209982-97-8

Basic information

• Product Name: methyl α-fluoro-3,5-difluorophenylacetate
• Synonyms: methyl α-fluoro-3,5-difluorophenylacetate
• CAS NO: 209982-97-8
• Molecular Weight: 204.149
• Mol File: 209982-97-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: methyl α-fluoro-3,5-difluorophenylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl α-fluoro-3,5-difluorophenylacetate(209982-97-8)
• EPA Substance Registry System: methyl α-fluoro-3,5-difluorophenylacetate(209982-97-8)

Safety Data

• Hazardous Substances Data: 209982-97-8(Hazardous Substances Data)

Upstream product

• 208259-37-4 methyl 2-(3,5-difluorophenyl)-2-hydroxyacetate 

Relevant articles and documents

CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.